The First Affiliated Hospital of Nanchang University
🇨🇳China
Clinical Trials
29
Active:1
Completed:4
Trial Phases
5 Phases
Early Phase 1:1
Phase 1:4
Phase 2:4
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Not Applicable
11 (45.8%)Phase 1
4 (16.7%)Phase 2
4 (16.7%)Phase 4
4 (16.7%)Early Phase 1
1 (4.2%)Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis
Not yet recruiting
- Conditions
- Robotic Surgical ProceduresRight Colon TumorsCancerLaparoscopic Abdominal Surgery
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Target Recruit Count
- 4000
- Registration Number
- NCT07029464
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Early Phase 1
Recruiting
- Conditions
- Relapsed/RefractoryMultiple Myeloma
- Interventions
- Biological: BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Target Recruit Count
- 12
- Registration Number
- NCT06999031
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
Not Applicable
Recruiting
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751966
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
Not Applicable
Recruiting
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06752057
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Phase 2
Recruiting
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751901
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found